Cargando…
Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
BACKGROUND: Pancreas cancer is one of most aggressive human cancers with the survival rate for patients with metastatic pancreas cancer at 5-6 months. The poor survival demonstrates a clear need for better target identification, drug development and new therapeutic strategies. Recent discoveries hav...
Autores principales: | Vo, Kevin, Amarasinghe, Barushi, Washington, Kay, Gonzalez, Adriana, Berlin, Jordan, Dang, Thao P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253061/ https://www.ncbi.nlm.nih.gov/pubmed/22074495 http://dx.doi.org/10.1186/1476-4598-10-138 |
Ejemplares similares
-
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
por: Cloughesy, Tim F, et al.
Publicado: (2008) -
Notch3 Cooperates With the EGFR Pathway to Modulate Apoptosis Through The Induction Of Bim
por: Konishi, Jun, et al.
Publicado: (2009) -
PTEN mediates Notch-dependent stalk cell arrest in angiogenesis
por: Serra, Helena, et al.
Publicado: (2015) -
PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
por: Cheng, Zhi Y, et al.
Publicado: (2008) -
Src kinase phosphorylates Notch1 to inhibit MAML binding
por: LaFoya, Bryce, et al.
Publicado: (2018)